The FDA has approved Skinvive by Juvéderm for improvement of neck appearance, marking the first indication outside facial rejuvenation for AbbVie's hyaluronic acid filler platform. The product is positioned as a smooth, injectable gel designed to address neck lines and skin texture — a clinical gap many practices have managed off-label or deferred to energy devices.
Injectables
FDA Approves Skinvive by Juvéderm for Neck Appearance — AbbVie Expands Filler Portfolio Beyond Face
Allergan Aesthetics gains clearance for injectable to improve neck lines and skin quality, opening a new revenue line for practices.

1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |